Meta Pixel

News and Announcements

Pacific Knowledge Systems IPO roadshow Kicks off with the hope to raise $22 Million

  • Published December 02, 2018 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Bombora Investment Management are the lead investor in an exciting IPO for a high growth and profitable healthcare technology company called Pacific Knowledge Systems (PKS).

The companies IPO roadshow kicked off last week with the aim to raise $22 Million. Bombora Investment Management are offering the opportunity to meet the company during the IPO roadshow.

About Bombora Investment Management are the lead investor in an exciting IPO for a high growth and profitable healthcare technology company called Pacific Knowledge Systems (PKS).

About Pacific Knowledge Systems

PKS is a healthcare technology company which provides a proprietary subscription based Clinical Decision Support (CDS) system called “RippleDown” that automates the human decision-making process in health care organisations. PKS represents a potential opportunity to participate in the large and fast growing global Healthcare IT solutions market.

In summary, PKS is profitable and has great growth ambitions with the RippleDown software product used by pathology and hospital departments to increase efficiency of patient interpretations and the financial accuracy of all billing movements.

 

RippleDown has two components that address a number of the key issues faced by healthcare organisations:

  • RippleDown Auditor: that enables operational efficiencies through a reduction in data entry errors; and
  • RippleDown Expert:  that allows faster patient throughput, better patient outcomes and mitigates succession risk.

The Offer

PKS is raising $22.0m from the IPO (Offer) and expects to commence trading in January 2019 under the ticker “PKS”

If you are interested in attending the roadshow, the company has provided a special allocation using the following link: www.netroadshow.com/nrs/home/#!/?show=d27efe24

If required, deal entry code is “PKS93”.

RippleDown has been successfully implemented at a range of healthcare organisations globally and has three partnerships with international channel partners Abbott, Phillips and Thermo-Fisher. It is a highly scalable, subscription-based technology offering with annuity style revenue streams.

PKS has a highly experienced board consisting of healthcare operators and investment professionals, including:

  • Mike Hill (Bombora)
  • Chris Smith (ex CEO of Cochlear)
  • Paul Williams (ex CIO of Healthscope)
  • Andrew Gray (Potentia Capital – Software Investor)
  • Neil Broekhuizen (Board of Bravura Limited and Monash IVF)

Register Interest

 

Capital Insights
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship

From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now